Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03860493 · ClinicalTrials.gov registry record
Feasibility of the IC-Flow Device for Fluorescent Perfusion Evaluation During Feasibility of the IC-Flow Device
A clinical trial, sponsored by The Cleveland Clinic.
- Completed
- Registry status
- 6
- Enrollment target
NCT03860493: Completed study, sponsored by The Cleveland Clinic.
NCT03860493 is a clinical trial that has completed, run by The Cleveland Clinic. The registered enrollment target is 6 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03860493 has completed, sponsored by The Cleveland Clinic.
- COMPLETED
- Registry status
- 6 participants
- Enrollment target
Study Summary
1. Primary Objective: Demonstrate that the IC-Flow Imaging device with Indocyanine Green (ICG) is a feasible technique when visualizing and identifying perfusion of organs when compared to The KARL STORZ VITOM II ICG System during open reconstructive surgical procedures 2. Secondary Objective: 1. Evaluate the mean Assessment of handling properties using The IC- Flow versus The VITOM II. 2. Evaluate the mean Surgeon preference Level using The IC- Flow tower, The IC-Flow Hand-held device versus The VITOM II.
Primary Outcome
The vascular perfusion of the tissue studied will be analyzed using the infra red light after injection of indocyanine green (ICG) by using both the Karl Storz Vitom II and the IC-Flow systems.
Interventions
- PROCEDURE Perfusion evaluation with indocyanine green
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2019-05-15 |
| Est. Completion | 2020-12-31 |
What the finished NCT03860493 record still lists
NCT03860493 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 6 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Perfusion evaluation with indocyanine green is the first listed.
NCT03860493 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03860493 about?
NCT03860493 is a clinical study titled "Feasibility of the IC-Flow Device for Fluorescent Perfusion Evaluation During Feasibility of the IC-Flow Device". 1. Primary Objective: Demonstrate that the IC-Flow Imaging device with Indocyanine Green (ICG) is a feasible technique when visualizing and identifying perfusion of organs when compared to The KARL STORZ VITOM II ICG System during open reconstructive surgical procedures 2. Secondary Objective: ...
What is the current status of trial NCT03860493?
This trial is currently completed. The enrollment target is 6 participants. The study started on 2019-05-15. Estimated completion is 2020-12-31.
What interventions are being tested in trial NCT03860493?
The interventions under investigation include: Perfusion evaluation with indocyanine green (PROCEDURE).
Who is sponsoring clinical trial NCT03860493?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI